Cobra Biologics, Pall Corporation and the Cell and Gene Therapy Catapult Win £1.5M Innovate UK Grant to Investigate Continuous Manufacturing for Gene Therapies
KEELE, England, PORT WASHINGTON, N.Y. and LONDON, Nov. 26, 2018 /PRNewswire/ — Cobra Biologics, an international contract development and manufacturing organization (CDMO) with a focus on advanced therapy medicinal products (ATMPs) has won a £1.5M shared grant from Innovate UK, the United Kingdom’s innovation agency. Co-winners, Pall Corporation, a global leader in filtration, separation and purification, and the Cell and Gene Therapy Catapult, an independent research and technology organization... Read more